pocketful logo light
pocketful logo light
Solara Active Pharma Sciences Ltd logo

Solara Active Pharma Sciences Ltd

NSE: SOLARA BSE: 541540

₹565.25

(1.46%)

Wed, 27 May 2026, 04:48 pm

mtf coin illustrationMTF 5x

Solara Active Pharma Sciences Share Price Live Chart

1 Day

(1.46%)

No Result Found

Summary

  • Market Cap

    2023.27

  • Net Profit

    0.54

  • P/B

    1.89

  • Sector P/E

    34.32

  • P/E

    3943.85

  • EV/EBITDA

    13.31

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    0.05

  • ROCE

    5.41

  • Debt/Equity

    0.89

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    344.03

  • Interest Cover

    1

Analysis

all

thumbs up icon

Pros

  • Solara Active Pharma Sciences's earnings growth is expected to exceed the low risk savings rate of 7.2%.
  • Solara Active Pharma Sciences's earnings are expected to exceed the low risk growth rate next year.
  • An improvement in Solara Active Pharma Sciences's performance (ROE) is expected over the next 3 years.
  • Solara Active Pharma Sciences's revenue growth is expected to exceed the India market average.
  • Solara Active Pharma Sciences is profitable, therefore cash runway is not a concern.
thumbs up icon

Cons

  • Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
  • No need to calculate the sustainability of Solara Active Pharma Sciences's dividends as it is not paying a notable one for India.
  • Solara Active Pharma Sciences is not paying a notable dividend for India, therefore no need to check if the payments are stable.
  • Solara Active Pharma Sciences's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
  • Solara Active Pharma Sciences's dividend is below the markets top 25% of dividend payers in India (3.08%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters42.0042.0042.0142.0137.94
FII11.5911.9813.5814.2514.63
DII3.753.642.692.622.61
Public42.6642.3741.7241.1144.81
Government0.000.000.000.000.00

Read More

Technical Analysis

RSI

55.52

MACD

18.65

50 DMA

493.19

200 DMA

550.48

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic640.60562.60529.20484.60451.20406.60328.60
Fibonacci562.60532.80514.40484.60454.80436.40406.60
Camarilla517.25510.10502.95484.60488.65481.50474.35

Pivots Level: Classic

R3

+156.00

640.60

R2

+78.00

562.60

R1

+44.60

529.20

484.60
484.60
Pivot Point
LTP: 545.80

S1

-33.40

451.20

S2

-78

406.60

S3

-156

328.60

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    550.05

  • 20-EMA

    536.08

  • 30-EMA

    524.62

  • 50-EMA

    512.74

  • 100-EMA

    513.72

  • 200-EMA

    532.40

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
15 May 2026board-meetingsAccounts
06 Feb 2026board-meetingsQuarterly Results
05 Nov 2025board-meetingsQuarterly Results
03 Sept 2025agm
29 Aug 2024agm
17 Aug 2024agmAnnual General Meeting18 Sept 2024
09 May 2024rights1:3 Rights Issue of Equity Shares15 May 2024
15 Apr 2024rightsRight Issue of Equity Shares15 May 2024
21 Aug 2023agm
08 Aug 2023agmAnnual General Meeting09 Sept 2023

Read More

Peer Comparison

Solara Active Pharma Sciences Ltd logo

Solara Active Pharma Sciences Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Solara Active Pharma Sciences Ltd About

Solara Active Pharma Sciences offers a diversified portfolio of high-value commercial APIs across more than 70 countries.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

2017

Headquarters

CEO

RAJAGOPALAN RAMAKRISHNAN

Employees

Contact

Website icon

Website

http://www.solara.co.in

Email icon

Email

investors@solara.co.in

Phone icon

Phone

91-22-27892924

Location icon

Location

201 Devavrata Sector 17 Vashi, Navi Mumbai, Mumbai, Maharashtra, 400703

Read More

Solara Active Pharma Sciences Ltd Company History

YearHistory
2017
  • The company was originally incorporated as SSL Pharma Sciences Limited under the Companies Act, 2013.
  • The company's name was changed to Solara Active Pharma Sciences Limited and a fresh certificate of incorporation was issued by the RoC.
2019
  • Solara Active Pharma Sciences successfully completed the US FDA inspection at the multi-product manufacturing facility at Cuddalore with zero 483s.
2021
  • Solara Active Pharma approved the acquisition of the balance 10.77% stake in Sequent Penems.
2023
  • Solara Active Pharma Sciences completed the WHO inspection at its Cuddalore facility.
2024
  • The company issued rights shares of Rs. 10 in the ratio of 1:3 at a premium of Rs. 365 per share.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
FSSA INDIAN SUBCONTINENT FUNDbulkSell224730538.1120 Jun 2025
SPIRACCA VENTURES LLPblockSell200000049516 Jun 2025
PRONOMZ VENTURES LLPblockBuy200000049516 Jun 2025
PRONOMZ VENTURES LLPbulkBuy200000049516 Jun 2025
SPIRACCA VENTURES LLPbulkSell200000049516 Jun 2025
BHATIA SURESHbulkSell20452749024 Feb 2025
AARTI BHATIAbulkBuy20452749024 Feb 2025
AARTI BHATIAblockBuy20452749024 Feb 2025
BHATIA SURESHblockSell20452749024 Feb 2025
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITEDbulkBuy200000049528 Jun 2024

Read More

Solara Active Pharma Sciences Ltd News

Solara Active Pharma Updates Board & Whistleblower Policies

Solara Active Pharma Sciences adopted a Board Evaluation Policy and amended its Whistle Blower Policy at its Board meeting held on May 15, 2026.

19 May 2026

companies

Solara Q4 FY26: Highest Revenue & EBITDA in Eight Quarters

Solara Active Pharma Sciences reports Q4 FY26 revenue of Rs. 387.29 crores (+40% YoY) and net profit of Rs. 9.60 crores; publishes newspaper advertisement for audited FY26 results.

16 May 2026

companies

Solara MD: Q4 FY26 Highest Revenue & EBITDA in 8 Quarters

Solara Active Pharma Sciences MD highlights Q4 FY26 as the best quarter in eight, with 12% QoQ and 40% YoY growth, recording highest revenue, gross margin, and EBITDA.

15 May 2026

companies

Solara Pharma Reappoints Auditors for FY 2026-27

Solara Active Pharma Sciences reappoints Grant Thornton Bharat LLP as Internal Auditors and Mr. K. Suryanarayanan as Cost Auditors for FY 2026-27, effective May 15, 2026.

15 May 2026

companies

Solara Q4FY26: Base Business Surges, Ibuprofen Drags

Solara Active Pharma Sciences Q4FY26 base business revenue rose 36% YoY to INR 3,070mn; overall revenue grew 40% YoY to INR 3,919mn. Ibuprofen unit posted negative 21% EBITDA. Bankers appointed for strategic review.

15 May 2026

companies

Read More